2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Colorectal Neoplasms, Hereditary Nonpolyposis
2
Colorectal Neoplasms
2
Recurrence
1
Psoriasis
1
Neoplasms
1
Lymphoma, Follicular
1
Inflammatory Bowel Diseases
1
Colonic Neoplasms
1
Colitis, Ulcerative
1
Adenoma
1
Interventions
Infliximab
6
etrolizumab
5
Adalimumab
4
golimumab
3
Nivolumab
3
CT-P13
3
Specimen Handling
2
Educational Status
2
Colonoscopy
2
vedolizumab
1
pembrolizumab
1
peficitinib
1
cabozantinib
1
Vitamin E
1
Sutures
1
Surgical Instruments
1
Standard of Care
1
Ringer's Lactate
1
Proctocolectomy, Restorative
1
Proctectomy
1
Practice Guidelines as Topic
1
Pneumococcal Vaccines
1
Platinum Compounds
1
Papillomavirus Vaccines
1
Narrow Band Imaging
1
NX-13
1
Methylprednisolone
1
Methods
1
Mesalamine
1
Medical Marijuana
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colitis, Ulcerative
×
Mesalamine
×
Clear all
NCT02093663
2021-06-09
PACE
Takeda
Phase 3
Completed
107 enrolled
18 charts